|
Originally published In Press as doi:10.1194/jlr.R400007-JLR200 on September 1, 2004
Journal of Lipid Research, Vol. 45, 1967-1974, November 2004
Copyright © 2004 by American Society for Biochemistry and Molecular Biology
A review of CETP and its relation to atherosclerosis
Greetje J. de Grooth*,
Anke H. E. M. Klerkx*,
Erik S. G. Stroes*,
Anton F. H. Stalenhoef ,
John J. P. Kastelein* and
Jan Albert Kuivenhoven1,*
* Department of Vascular Medicine, Academic Medical Centre, Amsterdam, The Netherlands
Department of Internal Medicine, University Medical Centre Nijmegen, Nijmegen, The Netherlands
1 To whom correspondence should be addressed. e-mail: j.a.kuivenhoven{at}amc.uva.nl
Although the atheroprotective role of HDL cholesterol (HDL-c) is well documented, effective therapeutics to selectively increase plasma HDL-c levels are not yet available. Recent progress in unraveling human HDL metabolism has fuelled the development of strategies to decrease the incidence and progression of coronary artery disease (CAD) by raising HDL-c. In this quest for novel drugs, cholesteryl ester transfer protein (CETP) represents a pivotal target. The role of this plasma protein in HDL metabolism is highlighted by the discovery that genetic CETP deficiency is the main cause of high HDL-c levels in Asian populations. The use of CETP inhibitors to effectively increase HDL-c concentration in humans was recently published and data with regard to the effect on human atherosclerosis are expected shortly.
This review discusses the potential of CETP inhibitors to protect against atherosclerosis in the context of the current knowledge of CETP function in both rodents and humans.
Abbreviations: Apo, apolipoprotein; CAD, coronary artery disease; CE, cholesteryl ester; CETP, cholesteryl ester transfer protein; CVD, cardiovascular disease; HDL-c, HDL cholesterol; LDL-c, LDL cholesterol; RCT, reverse cholesterol transport Supplementary key words atherosclerosis cardiovascular disease cholesteryl ester transfer protein coronary artery disease dyslipidemia

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Jahangiri, M. C. de Beer, V. Noffsinger, L. R. Tannock, C. Ramaiah, N. R. Webb, D. R. van der Westhuyzen, and F. C. de Beer
HDL Remodeling During the Acute Phase Response
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2009;
29(2):
261 - 267.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. W. F. Wilson
CETP Genes, Metabolic Effects, and Coronary Disease Risk
JAMA,
June 18, 2008;
299(23):
2795 - 2796.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. H Barnett
The importance of treating cardiometabolic risk factors in patients with type 2 diabetes
Diabetes and Vascular Disease Research,
March 1, 2008;
5(1):
9 - 14.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Tchoua, W. D'Souza, N. Mukhamedova, D. Blum, E. Niesor, J. Mizrahi, C. Maugeais, and D. Sviridov
The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport
Cardiovasc Res,
March 1, 2008;
77(4):
732 - 739.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Lee-Rueckert, R. Vikstedt, J. Metso, M. Jauhiainen, and P. T. Kovanen
Association of cholesteryl ester transfer protein with HDL particles reduces its proteolytic inactivation by mast cell chymase
J. Lipid Res.,
February 1, 2008;
49(2):
358 - 368.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Spielmann, A. S. Leon, D. C. Rao, T. Rice, J. S. Skinner, C. Bouchard, and T. Rankinen
CETP genotypes and HDL-cholesterol phenotypes in the HERITAGE Family Study
Physiol Genomics,
September 11, 2007;
31(1):
25 - 31.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Tanigawa, J. T. Billheimer, J.-i. Tohyama, Y. Zhang, G. Rothblat, and D. J. Rader
Expression of Cholesteryl Ester Transfer Protein in Mice Promotes Macrophage Reverse Cholesterol Transport
Circulation,
September 11, 2007;
116(11):
1267 - 1273.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. E. Borggreve, H. L. Hillege, G. M. Dallinga-Thie, P. E. de Jong, B. H.R. Wolffenbuttel, D. E. Grobbee, A. van Tol, R. P.F. Dullaart, and on behalf of the PREVEND Study Group
High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides
Eur. Heart J.,
April 4, 2007;
(2007)
ehm062v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. A. van der Steeg, G. K. Hovingh, A. H. E. M. Klerkx, B. A. Hutten, I. C. Nootenboom, J. H. M. Levels, A. van Tol, G. M. Dallinga-Thie, A. H. Zwinderman, J. J. P. Kastelein, et al.
Cholesteryl ester transfer protein and hyperalphalipoproteinemia in Caucasians
J. Lipid Res.,
March 1, 2007;
48(3):
674 - 682.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kontush and M. J. Chapman
Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis
Pharmacol. Rev.,
September 1, 2006;
58(3):
342 - 374.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. R Pedersen, G. Assmann, J.-P. Bassand, M J. Chapman, R. Erbel, and C. Sirtori
Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment
Diabetes and Vascular Disease Research,
September 1, 2006;
3(2_suppl):
S1 - S12.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. H.E.M. Klerkx, K. E. Harchaoui, W. A. van der Steeg, S. M. Boekholdt, E. S.G. Stroes, J. J.P. Kastelein, and J. A. Kuivenhoven
Cholesteryl Ester Transfer Protein (CETP) Inhibition Beyond Raising High-Density Lipoprotein Cholesterol Levels: Pathways by Which Modulation of CETP Activity May Alter Atherogenesis
Arterioscler. Thromb. Vasc. Biol.,
April 1, 2006;
26(4):
706 - 715.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Duffy and D. J. Rader
Emerging Therapies Targeting High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport
Circulation,
February 28, 2006;
113(8):
1140 - 1150.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Barter and J. J.P. Kastelein
Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular Disease
J. Am. Coll. Cardiol.,
February 7, 2006;
47(3):
492 - 499.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. S. Young
Lipids for Psychiatrists - an overview
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
66 - 75.
[Abstract]
[PDF]
|
 |
|
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|